[posting]36449226[/posting]Die Bioms Investor Relations Abteilung hat mir aufschlußreich geantwortet:
Bioms hat ein einzigartiges Produkt für Secundar MS!!!
Dear Mr. Reindl,
Thank you for your email and your continued interest in BioMS Medical.
The article you refer to discusses the Phase III results of Cladribine, which is a therapy for the treatment of patients with Relapsing Remitting Multiple Sclerosis.
BioMS Medical's therapy, dirucotide, is in Phase III trials for patients with Secondary Progressive Multiple Sclerosis (SPMS), for which there is currently no treatment, and it is currently the only novel agent for SPMS in Phase III clinical trials.
I hope this answers your question. Please do not hesitate to contact me if you have any additional questions.
Regards,
Amanda
Amanda Stadel, M.Sc. l Investor Relations Manager
Ph: 780-413-7152 Fax: 780-408-3040